Genetic testing company IMBdx has expanded its partnership with Big Pharma company AstraZeneca to advance liquid biopsy testing for metastatic castration-resistant prostate cancer (mCRPC) patients under a project called PROSPER 2.0.

As part of the PROSPER 2.0 initiative, both companies are actively investigating methods to enhance knowledge and understanding among clinicians and patients regarding the benefits and significance of circulating tumor DNA (ctDNA) testing for guiding the utilization of targeted therapies in advanced prostate cancer.

Additionally, both companies are focusing on promoting awareness of the specific capabilities and advantages offered by the AlphaLiquid HRR ctDNA test. IMBdx offers the AlphaLiquid HRR test, a blood-based, next-generation sequencing assay that detects gene alterations associated with homologous recombination repair.

IMBdx is a precision oncology company that specializes in diagnosing tumors through blood samples. It uses advanced technology to analyze the genomic profile of tumor DNA and provide personalized information for therapy selection and monitoring. IMBdx's comprehensive suite of ctDNA tests supports patients throughout their cancer journey and assists healthcare professionals, researchers, and drug developers in addressing unmet needs. It uses AI and analysis methods to predict cancer prognosis and treatment response.